Stories
Ashwagandha Study on COVISHIELD Recipients: 24-Week Impact on Liver-Kidney Revealed
N
News18•29-09-2026, 19:15
Ashwagandha Study on COVISHIELD Recipients: 24-Week Impact on Liver-Kidney Revealed
- •A new clinical study published in Frontiers in Medicine investigated the safety and tolerability of 24 weeks of standardized Ashwagandha root extract use.
- •The multicenter, randomized, and placebo-controlled trial included 1,200 healthy individuals aged 18 to 70 years who had received the COVISHIELD vaccine.
- •Participants received either 500 mg of standardized aqueous Ashwagandha root extract or a placebo daily; 86% completed the study.
- •Liver and kidney function tests, along with other health parameters, remained within normal reference ranges, showing no drug-related harm from Ashwagandha.
- •Mild to moderate adverse events were reported, but researchers deemed them not serious and not related to Ashwagandha; no significant boost in vaccine immunity was observed.
Key Questions Answered
According to a clinical study published on August 20, 2026, liver and kidney function tests for participants taking a daily 500 mg standardized Ashwagandha root extract remained within prescribed reference ranges, showing no drug-related harm.
No, taking Ashwagandha did not demonstrate any clear or statistically significant additional benefit to vaccine-induced immunity, which researchers attributed to strong pre-existing immunity and prior SARS-CoV-2 exposure.
Participants reported mild to moderate adverse events such as weight changes, mouth ulcers, gastrointestinal discomfort, increased sleepiness, and dizziness, but these were comparable to the placebo group.
